膀胱内注射Nadofaragene Firadenovec治疗卡介苗无反应性非肌层浸润性膀胱癌的疗效:3期试验5年随访
这项开放标签3期试验纳入157例卡介苗无反应性非肌层浸润性膀胱癌患者,分原位癌±Ta/T1组(n=107)和无原位癌的Ta/T1组(n=50),接受Nadofaragene Firadenovec 75 mL(3×10^11 vp/mL)每3个月膀胱内灌注。中位随访50.8个月,57个月时原位癌组高级别无复发率为5.8%,Ta/T1组为15%;60个月时保留膀胱生存率近半,仅5例进展为肌层浸润性疾病,结论认为该疗法安全且可保留膀胱。
要点
- 57个月时高级别无复发率原位癌组5.8%(95%CI 2.2-12.2),Ta/T1组15%(95%CI 6.1-27.8)
- 60个月时无膀胱切除术生存率总体49%(95%CI 40.0-57.1),原位癌组43%,Ta/T1组59%
- 60个月总生存率80%,仅5例(原位癌4例、Ta/T1组1例)进展为肌层浸润性疾病
核心结论
- 60个月时Nadofaragene Firadenovec-vncg使近半数患者得以保留膀胱,并被证明是卡介苗无反应性非肌层浸润性膀胱癌的安全选择。
研究设计与样本
- 开放标签3期试验(NCT02773849),在美国33个中心入组157例卡介苗无反应性非肌层浸润性膀胱癌患者,其中151例纳入疗效分析,分原位癌±Ta/T1组(n=107)和无原位癌的Ta/T1组(n=50)。
主要发现
- 中位随访50.8个月(四分位距39.1-60.0),27%的患者接受≥5次灌注,7.6%的患者治疗≥57个月。
- 57个月时高级别无复发率在原位癌组为5.8%(95%CI 2.2-12.2),在高级别Ta/T1组为15%(95%CI 6.1-27.8)。
- Kaplan-Meier估计的57个月高级别无复发生存率在原位癌组为13%(95%CI 6.9-21.5),在Ta/T1组为33%(95%CI 19.5-46.6)。
- 60个月无膀胱切除术生存率总体为49%(95%CI 40.0-57.1),原位癌组为43%(95%CI 32.2-53.7),Ta/T1组为59%(95%CI 43.1-71.4)。
- 60个月总生存率总体为80%(95%CI 71.0-86.0),原位癌组为76%(95%CI 64.6-84.5),Ta/T1组为86%(95%CI 70.9-93.5);仅5例患者(原位癌4例、Ta/T1组1例)出现临床进展为肌层浸润性疾病。
关键数值与推荐
- 患者接受Nadofaragene Firadenovec 75 mL(3×10^11 vp/mL)膀胱内灌注,每3个月一次,同时进行膀胱镜和细胞学评估,对持续高级别无复发者继续治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Nadofaragene firadenovec-vncg is a nonreplicating adenoviral vector-based gene therapy for bacillus Calmette-Guérin (BCG)-unresponsive carcinoma in situ (CIS) with/without high-grade Ta/T1. We report outcomes following 5 years of planned follow-up. MATERIALS AND METHODS: This open-label phase 3 trial (NCT02773849) enrolled patients with BCG-unresponsive nonmuscle-invasive bladder cancer in 2 cohorts: CIS ± Ta/T1 (CIS; n = 107) and Ta/T1 without CIS (Ta/T1 cohort; n = 50). Patients received 75 mL (3 × 1011 vp/mL) nadofaragene firadenovec intravesically once every 3 months with cystoscopy and cytology assessments, with continued treatment offered to those remaining high grade recurrence-free (HGRF). RESULTS: One hundred fifty-seven patients were enrolled from 33 US sites (n = 151 included in efficacy analyses). Median follow-up was 50.8 months (interquartile range 39.1-60.0), with 27% receiving ≥ 5 instillations and 7.6% receiving treatment for ≥ 57 months. Of patients with CIS 5.8% (95% CI 2.2-12.2) were HGRF at month 57, and 15% (95% CI 6.1-27.8) of patients with high-grade Ta/T1 were HGRF at month 57. Kaplan-Meier-estimated HGRF survival at 57 months was 13% (95% CI 6.9-21.5) and 33% (95% CI 19.5-46.6) in the CIS and Ta/T1 cohorts, respectively. Cystectomy-free survival at month 60 was 49% (95% CI 40.0-57.1): 43% (95% CI 32.2-53.7) in the CIS cohort and 59% (95% CI 43.1-71.4) in the Ta/T1 cohort. Overall survival at 60 months was 80% (71.0, 86.0): 76% (64.6-84.5) and 86% (70.9-93.5) in the CIS and Ta/T1 cohorts, respectively. Only 5 patients (4 with CIS and 1 with Ta/T1) experienced clinical progression to muscle-invasive disease. CONCLUSIONS: At 60 months, nadofaragene firadenovec-vncg allowed bladder preservation in nearly half of the patients and proved to be a safe option for BCG-unresponsive nonmuscle-invasive bladder cancer.
引用
- Narayan VM, Boorjian SA, Alemozaffar M, et al. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024. PMID: 38704840. doi:10.1097/JU.0000000000004020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。